Clinical Trial

Correlation Studies on Human Body Composition Based on Bioequivalence or Pharmacokinetic Trials

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this observational study is to investigate the impact of body composition on the absorption, distribution, and metabolism of drugs. The primary question it seeks to answer is: Does body composition affect the absorption, distribution, and metabolism of drugs? By combining pharmacokinetic parameters and adverse drug reactions, the study will analyze differences in the metabolism of drugs under various body composition conditions. During the Phase I clinical trial, under the guidance of the researchers, subjects will use the non-invasive InBody S10 body composition analyzer to obtain body composition data, including but not limited to inorganic salts, muscle mass, lean body mass, body weight, and body fat percentage.
Trial Details
NCT Number NCT07611929
Lead Sponsor Second Affiliated Hospital of Wenzhou Medical University
Conditions Healhty
Enrollment 3,000 participants
Start Date 2024-10-05
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-28